drugset / Trial / NCT06182267

Maximal Use Study to Determine the Pharmacokinetics of L-arginine After Exaggerated Oral Use of COL101

NCT06182267

Phase 1 Completed 29 enrolled Colgate Palmolive
RandomizedCrossoverQuadruple-blindTreatment

Summary

Pharmacokinetic (PK) study of L-arginine after exaggerated oral use of the novel dentifrice product COL101 after repeated daily applications in healthy adult subjects.

Timeline

Start
2023-11-27
Primary completion
2023-12-22
Completion
2023-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject L-arginine Small molecule 8 % Oral
Background sodium fluoride Unknown 0.24 % Oral

Indications